---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromic’s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article
quality: 0
heat: -1
published: false

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

related:
  - title: "Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine"
    excerpt: "Kiromic announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Proprietary AI Engine"
    publishedDateTime: 2021-05-21T15:59:00Z
    webUrl: "https://www.businesswire.com/news/home/20210521005209/en/Kiromic-Announces-Identification-of-Novel-Targets-for-Allogeneic-CAR-Gamma-Delta-T-cell-Therapy-in-Solid-Tumors-Utilizing-Kiromic’s-Proprietary-Artificial-Intelligence-Engine"
    type: article
    provider:
      name: Business Wire
      domain: businesswire.com
    quality: 0

secured: "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;BaArZOrv62VLCNAS3nR/gw=="
---

